Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2023

Innocuité et efficacité du bimekizumab chez les patients atteints de rhumatisme psoriasique actif : Résultats à trois ans d'un essai contrôlé randomisé de phase IIb et de son étude de prolongation ouverte

Arthritis Rheumatol. 2022 doi: 10.1002/art.42280

Ink B,

This study highlighted that the safety of bimekizumab in patients with PsA over 3 years of treatment was consistent with the previous 48-week results, as well as other recently published studies of IL-17 inhibitors in PsA patients.

Keywords:

Bimekizumab chez des patients atteints de rhumatisme psoriasique actif et ayant déjà présenté une réponse inadéquate ou une intolérance aux inhibiteurs du facteur de nécrose tumorale : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo (BE COMPLETE))

Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0

Ink B,

This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.

Keywords:

Bimekizumab chez des patients atteints de rhumatisme psoriasique, naïfs de traitement biologique : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo (BE OPTIMAL)

Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9

Ink B,

This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.